Our understanding of the genetic and molecular mechanisms that lead to cancer have improved greatly over the past decade thanks to significant advancements. Despite this, only 10 percent of the oncology drugs approved by the U.S. Food and Drug Administration (FDA) demonstrate an overall survival benefit. Now, precision medicine is making waves and shifting how early-phase oncology trials are conducted, including many Phase 1 trials with preliminary response rates. This white paper addresses clinical trials in precision medicine and explores the expanding role of adaptive trial designs in Phase 1 and Phase 2 oncology studies. Download the full white paper here.